Cancerworld Magazine
  • About the Magazine
    • Editorial Team
    • Leadership and Management
    • Events
    • Magazine
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
    • Partnership
    • Supported contents
  • Media Corner
    • Journalist Cancer Guide
    • Cancer Journalism Award
    • Cancer Journalist Grant
SUBSCRIBE FOR FREE
Facebook
Twitter
LinkedIn
Cancerworld Magazine
Cancerworld Magazine
  • About the Magazine
    • Editorial Team
    • Leadership and Management
    • Events
    • Magazine
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
    • Partnership
    • Supported contents
  • Media Corner
    • Journalist Cancer Guide
    • Cancer Journalism Award
    • Cancer Journalist Grant
Cancerworld Magazine > News > Combined therapies offer the key to drug-resistant cancer
  • News

Combined therapies offer the key to drug-resistant cancer

  • 5 October 2020
  • Janet Fricker
Combined therapies offer the key to drug-resistant cancer
Total
0
Shares
0
0
0
0
0

For the first time, an investigator initiated phase 1b study tested the combination of the PARP inhibitor olaparib, and the AKT inhibitor capivasertib, and showed this combination was well tolerated and achieved durable responses in patients with treatment-refractory breast, ovarian and prostate cancers. The results were published in the journal Cancer Discovery (Yap TA et al. Cancer Discov 2020).

“Our study establishes the potential of a combination of two precision medicines for patients whose tumours have stopped responding to existing drugs. The combination of olaparib and capivasertib works by attacking two fundamental weaknesses in cancer, and could potentially be used to treat patients with several common tumours,” explains Johann de Bono, senior author of the study from the Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London.

The utility of PARP inhibitor monotherapy has been limited by the emergence of drug resistance and generally short-lived anti-tumour responses. The BRCA family of proteins are involved in DNA repair, but many cancer cells have mutations in BRCA1 or BRCA2.  PARP (poly-ADP ribose polymerase) is important in DNA repair, and can be targeted by PARP inhibitors. When a BRCA deficient cell is exposed to a PARP inhibitor, this disrupts two of the most important mechanisms responsible for repairing DNA, leading to cell death in a process known as ‘synthetic lethality’. Cancer cells can escape the control of PARP inhibitors leading to the development of resistance. The AKT inhibitor capivasertib, which targets the PI3K-AKT pathway, can increase disruption of BRCA and thereby further destabilise DNA repair mechanisms and increase sensitivity of cells to PARP inhibition.

In this study from four major UK cancer centres, 64 patients with a range of treatment-refractory advanced solid tumours including breast, ovarian and prostate cancers, were recruited into the dose-escalation arm (n=20) or the dose-expansion arm (n=44). For the dose-escalation arm, patients received increase doses of capivasertib after each cycle in combination with a fixed olaparib dose provided no grade 2 or worse toxicities were observed.

Results showed that the combination was well tolerated, and that 45% of the patients whose response could be assessed (25 out of 56 patients) achieved clinical benefit (RECIST complete or partial response criteria or stable disease greater than four months). Treatment-related toxicities were reversible and mainly GI-related, including diarrhoea, mucositis, nausea, and anorexia.

The team are now planning further later-stage clinical trials to assess this drug combination in patients who do not have AKT aberration or DNA repair defects. The recommended phase II dose for the two schedules were olaparib 300mg twice daily with either capivasertib 400 mg twice daily four days on, 3 days off, or capivasertib 650 mg twice daily, two days on, five days off.

“The trial design used in the combined drug study is very innovative”, comments Aoife Regan, Head of the ECMC Programme Office at Cancer Research UK. In a traditional 3+3 dose-escalation study, starting doses are usually low and given to the first three patients to see how they react. If there is no toxicity, the dose is increased and given to the next three patients, and so on until at least two patients among a cohort of three experience dose-limiting toxicities. “This means that in the dose-escalation part of a conventional study the majority of patients don’t receive a potentially therapeutic dose level. However, with this methodology, a patient is given the first low dose, then in the same patient the dose is increased the next time a dose is due. The result is that more patients receive potentially therapeutic doses of the drug,” says Regan. She continues, “Patients have a variety of responses to these drugs, and we don’t know why. The level of molecular data for every patient in this study will help understand how these drugs are working in different patients, and so, how to improve combination strategies in the future.”

The Institute of Cancer Research says that the study represents ‘an exemplar’ of the type of research they will be undertaking in their new Centre for Cancer Drug Discovery, which aims to use combination treatments to overcome drug resistance.

 

Illustration by Sara Corsi

Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Related Topics
  • AKT inhibitor
  • BRCA mutations
  • combination therapy
  • PARP inhibitor
  • phase I study
Janet Fricker

Janet Fricker is a medical writer specialising in oncology and cardiology. After researching articles for Cancerworld she runs, swims, and eats porridge.

Previous Article
  • News

New European Code of Cancer Practice defines patient rights along the cancer pathway

  • 23 September 2020
  • Janet Fricker
View Post
Next Article
  • News

Metastatic prostate cancer: cabazitaxel shows quality of life benefits over both abiraterone and enzalutamide

  • 6 October 2020
  • Janet Fricker
View Post
You May Also Like
View Post
  • News

Study highlights need to reanalyse genomics and genetics of metastatic tumours

  • Janet Fricker
  • 27 January 2023
View Post
  • News

Current cervical cancer screening paradigm fails older women

  • Janet Fricker
  • 26 January 2023
View Post
  • News

Call-to-arms for Europe to provide essential paediatric anti-cancer medicines

  • Janet Fricker
  • 9 January 2023
View Post
  • News

Exercise-stimulated myokine production can extend survival in advanced prostate cancer

  • Janet Fricker
  • 9 January 2023
View Post
  • News

Five San Antonio take-aways to improve care of breast cancer patients

  • Janet Fricker
  • 16 December 2022
View Post
  • News

Repurposed drug combination reduces risk of recurrence following surgery for colorectal cancer

  • Janet Fricker
  • 16 December 2022
View Post
  • News

Aerobic activity to outcompete metastasis 

  • Janet Fricker
  • 2 December 2022
View Post
  • News

Ending cancer inequalities: European summit showcases new tools to inform policy

  • Anna Wagstaff
  • 30 November 2022

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

search
or search in Cancerworld archive
Newsletter

Subscribe free to
Cancerworld!

We'll keep you informed of the latest features and news with a fortnightly email

Subscribe now
Latest News
  • Study highlights need to reanalyse genomics and genetics of metastatic tumours
    • 27 January 2023
  • Current cervical cancer screening paradigm fails older women
    • 26 January 2023
  • Call-to-arms for Europe to provide essential paediatric anti-cancer medicines
    • 9 January 2023
  • Exercise-stimulated myokine production can extend survival in advanced prostate cancer
    • 9 January 2023
  • Five San Antonio take-aways to improve care of breast cancer patients
    • 16 December 2022
Article
  • The cancer patients still struggling to access drugs in the wake of anti-corruption reforms
    • 27 January 2023
  • Immunotherapy: outcomes of ultra low-dose trial offer hope for better global access
    • 26 January 2023
  • Cervical cancer elimination efforts boosted by simpler ways to identify and treat pre-cancerous lesions
    • 12 January 2023
Latest printed issue
Social

Would you follow us ?

Contents
  • Hansjörg Senn of St Gallen: A practice-changing career
    • 3 February 2023
  • AI in Genomics and Reporting for Clinical Practice
    • 26 January 2023
  • Telemedicine in Cancer Care: Monitoring, Follow-Up,Tele-Rehabilitation, Palliative and Supportive Care
    • 23 January 2023
MENU
  • About the Magazine
    • Editorial Team
    • Leadership and Management
    • Events
    • Magazine
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
    • Partnership
    • Supported contents
  • Media Corner
    • Journalist Cancer Guide
    • Cancer Journalism Award
    • Cancer Journalist Grant
Cancerworld Magazine
  • About the Magazine
  • Articles
  • Media Corner
  • Privacy Policy
  • Cookie Policy

Cancerworld is funded by SPCC Sharing Progress in Cancer Care | Via Vincenzo Vela 6, 6500 Bellinzona - Switzerland | info@spcc.net

Archivio Cancerworld

Input your search keywords and press Enter.